AAAAAA

   
Results: 1-23 |
Results: 23
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study
Authors: Papakostas, P Kouroussis, C Androulakis, N Samelis, G Aravantinos, G Kalbakis, K Sarra, E Souglakos, J Kakolyris, S Georgoulias, V
Citation: P. Papakostas et al., First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study, EUR J CANC, 37(15), 2001, pp. 1833-1838
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study
Authors: Alexopoulos, A Kouroussis, C Malamos, N Kakolyris, S Kalbakis, K Kosmas, C Mavroudis, D Agelaki, S Vlachonicolis, J Sarra, E Rigatos, G Georgoulias, V
Citation: A. Alexopoulos et al., Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study, ANN ONCOL, 12(6), 2001, pp. 793-798
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
Authors: Mavroudis, D Papadakis, E Veslemes, M Tsiafaki, X Stavrakakis, J Kouroussis, C Kakolyris, S Bania, E Jordanoglou, J Agelidou, M Vlachonicolis, J Georgoulias, V
Citation: D. Mavroudis et al., A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer, ANN ONCOL, 12(4), 2001, pp. 463-470
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer
Authors: Stathopoulos, GP Mavroudis, D Tsavaris, N Kouroussis, C Aravantinos, G Agelaki, S Kakolyris, S Rigatos, SK Karabekios, S Georgoulias, V
Citation: Gp. Stathopoulos et al., Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer, ANN ONCOL, 12(1), 2001, pp. 101-103
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors
Authors: Kouroussis, C Kakolyris, S Mavroudis, D Androulakis, N Kalbakis, K Agelaki, S Sarra, E Souglakos, J Christodoulakis, M Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors, AM J CL ONC, 24(4), 2001, pp. 404-407
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
Authors: Agelaki, S Kakolyris, S Palamidas, P Kouroussis, C Mavroudis, D Kalbakis, K Georgoulias, V Raptis, A
Citation: S. Agelaki et al., A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer, LUNG CANC, 34(1), 2001, pp. 133-139
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
Authors: Kakolyris, S Papadakis, E Tsiafaki, X Kalofonos, C Rapti, A Toubis, M Bania, E Kouroussis, C Chainis, K Androulakis, N Agelaki, S Sarra, E Vardakis, N Georgoulias, V
Citation: S. Kakolyris et al., Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study, LUNG CANC, 32(2), 2001, pp. 179-187
A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors
Authors: Kakolyris, S Kouroussis, C Souglakos, J Mavroudis, D Agelaki, S Kalbakis, K Androulakis, N Vardakis, N Vamvakas, L Georgoulias, V
Citation: S. Kakolyris et al., A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors, ONCOL-BASEL, 61(4), 2001, pp. 265-270
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study
Authors: Kouroussis, C Souglakos, J Kakolyris, S Mavroudis, D Malamos, N Kalbakis, K Androulakis, N Agelaki, A Vardakis, N Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study, ONCOL-BASEL, 61(1), 2001, pp. 36-41
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer
Authors: Kakolyris, S Souglakos, J Kouroussis, C Androulakis, N Mavroudis, D Kalbakis, K Kotsakis, A Vardakis, N Koukourakis, M Romanos, J Georgoulias, V
Citation: S. Kakolyris et al., A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer, ONCOL-BASEL, 60(3), 2001, pp. 207-213
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: Two parallel multicenter phase II trials
Authors: Agelaki, S Bania, H Kouroussis, C Blazoyiannakis, G Sougalkos, J Tsiafaki, X Harpidou, A Kalbakis, K Rapti, A Androulakis, N Sarra, E Georgoulias, V Papadakis, E
Citation: S. Agelaki et al., Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: Two parallel multicenter phase II trials, ONCOL-BASEL, 60(3), 2001, pp. 235-241
Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer
Authors: Papadimitriou, CA Kouroussis, C Moulopoulos, LA Vlahos, G Rodolakis, A Kiamouris, C Diakomanolis, E Gika, D Michalas, S Dimopoulos, MA
Citation: Ca. Papadimitriou et al., Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer, CANCER, 92(7), 2001, pp. 1856-1863
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
Authors: Kalbakis, K Kouroussis, C Kakolyris, S Mavroudis, D Souglakos, J Agelaki, S Vamvakas, L Christodoulakis, M Stylianou, K Georgoulias, V
Citation: K. Kalbakis et al., Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes, BR J CANC, 85(6), 2001, pp. 798-802
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
Authors: Kakolyris, S Kouroussis, C Kalbakis, K Mavroudis, D Souglakos, J Vardakis, N Kremos, S Georgoulias, V
Citation: S. Kakolyris et al., Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin, ANN ONCOL, 11(6), 2000, pp. 757-760
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Authors: Mavroudis, D Alexopoulos, A Ziras, N Malamos, N Kouroussis, C Kakolyris, S Agelaki, S Kalbakis, K Tsavaris, N Potamianou, A Rigatos, G Georgoulias, V
Citation: D. Mavroudis et al., Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study, ANN ONCOL, 11(10), 2000, pp. 1249-1254
Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
Authors: Koukourakis, MI Kyrias, G Kakolyris, S Kouroussis, C Frangiadaki, C Giatromanolaki, A Retalis, G Georgoulias, V
Citation: Mi. Koukourakis et al., Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study, J CL ONCOL, 18(11), 2000, pp. 2226-2233
A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Authors: Kouroussis, C Agelaki, S Mavroudis, D Souglakos, J Kakolyris, S Kalbakis, K Vardakis, N Reppa, D Hatzidaki, D Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose escalation study of weekly docetaxel in patients with advanced solid tumors, CANC CHEMOT, 46(6), 2000, pp. 488-492
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy - A report of five cases
Authors: Kouroussis, C Samonis, G Androulakis, N Souglakos, J Voloudaki, A Dimopoulos, MA Kotsakis, T Kakolyris, S Kalbakis, K Georgoulias, V
Citation: C. Kouroussis et al., Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy - A report of five cases, AM J CL ONC, 23(3), 2000, pp. 309-313
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
Authors: Kouroussis, C Xydakis, E Potamianou, A Giannakakis, T Kakolyris, S Agelaki, S Sara, E Malamos, N Alexopoulos, A Mavroudis, D Samonis, G Papadouris, S Georgoulias, V Panagos, G
Citation: C. Kouroussis et al., Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study, ANN ONCOL, 10(5), 1999, pp. 547-552
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
Authors: Kouroussis, C Androulakis, N Kakolyris, S Souglakos, J Kotsakis, T Mavroudis, D Katsogridakis, K Vardakis, N Hatzidaki, D Samonis, G Vlachonikolis, J Georgoulias, V
Citation: C. Kouroussis et al., Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer, J CL ONCOL, 17(3), 1999, pp. 862-869
Front-line treatment of advanced non-small-cell lung cancer with docetaxeland gemcitabine: A multicenter phase II trial
Authors: Georgoulias, V Kouroussis, C Androulakis, N Kakolyris, S Dimopoulos, MA Papadakis, E Bouros, D Apostolopoulou, F Papadimitriou, C Agelidou, A Hatzakis, K Kalbakis, K Kotsakis, A Vardakis, N Vlachonicolis, J
Citation: V. Georgoulias et al., Front-line treatment of advanced non-small-cell lung cancer with docetaxeland gemcitabine: A multicenter phase II trial, J CL ONCOL, 17(3), 1999, pp. 914-920
Spontaneous spondylodiscitis caused by Klebsiella pneumoniae
Authors: Kouroussis, C Georgoulias, V Souglakos, J Simvoulakis, E Karabekios, S Samonis, G
Citation: C. Kouroussis et al., Spontaneous spondylodiscitis caused by Klebsiella pneumoniae, INFECTION, 27(6), 1999, pp. 368-369
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial
Authors: Alexopoulos, K Kouroussis, C Androulakis, N Papadakis, E Vaslamatzis, M Kakolyris, S Samelis, G Patila, E Vossos, A Samantas, E Georgoulias, V
Citation: K. Alexopoulos et al., Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial, CANC CHEMOT, 43(3), 1998, pp. 257-262
Risultati: 1-23 |